PMID- 36741213
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230207
IS  - 2150-0878 (Print)
IS  - 2150-0886 (Electronic)
IS  - 2150-0878 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Jan
TI  - Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
PG  - 82-87
LID - 10.6004/jadpro.2023.14.1.8 [doi]
AB  - Treatment options are limited for patients with anemia associated with lower-risk 
      myelodysplastic syndromes (LR-MDS). The recent approval of luspatercept for the 
      treatment of anemia associated with very low-to intermediate-risk MDS with ring 
      sideroblasts (RS) or with myelodysplastic/myeloproliferative neoplasm with RS and 
      thrombocytosis has provided adult patients and practitioners with a much-needed 
      new therapeutic option. Luspatercept is a first-in-class erythroid maturation 
      agent that exerts its effects on later stages of erythropoiesis. In the phase III 
      MEDALIST trial of patients with LR-MDS with RS, luspatercept (starting dose 1 
      mg/kg) demonstrated substantial clinical benefit (38% of patients treated with 
      luspatercept vs. 13% of those treated with placebo [p < .001] achieved 
      transfusion independence for >/= 8 weeks during the first 24 weeks of treatment) 
      and a favorable safety profile. The most common adverse events (AEs), including 
      fatigue, asthenia, dizziness, and diarrhea, were more frequent during the first 4 
      treatment cycles and subsequently declined. This review provides a comprehensive 
      overview of luspatercept treatment administration, including the mechanism of 
      action, efficacy and safety data, management of dosing, and AEs associated with 
      luspatercept treatment of patients with LR-MDS.
CI  - (c) 2023 Harborside.
FAU - Tinsley-Vance, Sara M
AU  - Tinsley-Vance SM
AD  - Moffitt Cancer Center, Tampa, Florida.
FAU - Davis, Mark
AU  - Davis M
AD  - Texas Oncology-Southwest Fort Worth, Fort Worth, Texas.
FAU - Ajayi, Olalekan
AU  - Ajayi O
AD  - Highlands Oncology Group, Rogers, Arkansas.
LA  - eng
PT  - Journal Article
DEP - 20230201
PL  - United States
TA  - J Adv Pract Oncol
JT  - Journal of the advanced practitioner in oncology
JID - 101550346
PMC - PMC9894202
COIS- The authors received editorial and writing support from Rachel Klukovich, PhD, 
      from Excerpta Medica, funded by Bristol Myers Squibb, Princeton, NJ, USA. The 
      authors are fully responsible for all content and editorial decisions for this 
      manuscript. Dr. Tinsley-Vance has received support from Gulf Coast Community 
      Foundation Grant, National Institute of Nursing Research-K23 Grant, and Moffitt 
      Cancer Center Foundation. She has served as a consultant for AbbVie, Agios, 
      Bristol Myers Squibb, CTi, Incyte, Jazz, and Novartis; and on speakers bureaus 
      for Astellas, Bristol Myers Squibb, CTi, Incyte, and Jazz. Mr. Davis has served 
      as a consultant or on speakers bureaus for Bristol Myers Squibb, GlaxoSmithKline, 
      Incyte, Janssen, Karyopharm Therapeutics, and Takeda. Dr. Ajayi has served as a 
      consultant for Bayer, Bristol Myers Squibb, and Guidepoint; a speaker for 
      Astellas; and received advisory board funding from Integra Connect.
EDAT- 2023/02/07 06:00
MHDA- 2023/02/07 06:01
PMCR- 2023/01/01
CRDT- 2023/02/06 03:27
PHST- 2023/02/06 03:27 [entrez]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/07 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 2023.14.1.8 [pii]
AID - 10.6004/jadpro.2023.14.1.8 [doi]
PST - ppublish
SO  - J Adv Pract Oncol. 2023 Jan;14(1):82-87. doi: 10.6004/jadpro.2023.14.1.8. Epub 
      2023 Feb 1.